29/11/2025
Hiatal hernia and reflux
A. Medical Management (First-line for GERD):
1. Proton Pump Inhibitors (PPIs): Gold standard for esophagitis healing and symptom control.
*Limitation: Up to 30% of patients have a suboptimal response. Large hepatic hiatus reduces their effectiveness.
2. H2 Receptor Antagonists (H2RAs): Ranitidine, Famotidine. Alternative for mild/intermittent or nocturnal symptoms.
3. Antacids/Alginates: Rapid but transient symptomatic relief.
4. Lifestyle Modifications:
Weight loss (strong evidence).
Elevate the head of the bed.
Avoid large/fatty meals, chocolate, caffeine, mint, citrus fruits, alcohol, and to***co.
Do not lie down for 2-3 hours after eating. B. Endoscopic Management:
1. Esophageal Dilation: Primary treatment for symptomatic peptic stricture. Requires long-term PPI therapy to prevent recurrence.
2. Treatment of Barrett's Esophagus:
Periodic endoscopic surveillance according to the degree of dysplasia.
Endoscopic Mucosal Resection (EMR): For high-grade dysplasia or visible intramucosal cancer.
Radiofrequency Ablation (RFA) or Cryotherapy: Treatment of choice for high-grade dysplasia and persistent low-grade dysplasia in Barrett's esophagus. Effective in eliminating metaplasia and reducing the risk of cancer.
C. Surgical Management (Fundoplication):
Main Indications:
GERD refractory to maximum doses of PPIs with good symptom-reflux correlation (positive pH monitoring).
Intolerance to or serious adverse effects from PPIs.
Presence of a large (>2 cm) symptomatic or complicated hiatal hernia (especially paraesophageal hiatal hernia).
Complications (recurrent peptic stricture despite PPIs, Barrett's esophagus with dysplasia).
Need for chronic treatment in young patients.
Technique: Laparoscopic (current standard). Complete (Nissen 360°) or partial (Toupet 270°, Dor anterior) fundoplication.
Efficacy: High success rate in symptom and esophagitis control (>85-90% at 5-10 years in expert centers). Better results in patients with a previous response to PPIs and a proven hiatal hernia.